Close

Innovative Safety Application to Trend and Graph Laboratory Values from ICON plc

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

McKesson Acquires Controlling Stake in PRISM Vision

McKesson Corporation has announced its agreement to acquire a...

CluePoints Launches Medical & Safety Review (MSR) Software to Revolutionize Clinical Data Review

CluePoints continues to transform clinical trial review and leverage its...

ML And AI Transforming Pharmaceutical R&D And Drug Discovery

Richard Lee, Director, Core Technology and Capabilities, ACD/Labs, says...

TraceLink’s Magnum Release of Platform for Supply Chain Management

TraceLink, the largest end-to-end digital network platform for intelligent...

ICON plc, a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced the launch of the ICOLabs™ Medical Review Application (IMRA) an innovative web based laboratory application that enables more efficient use of medical monitoring time. The application is ICON’s latest innovation in the drive to expedite the medical management of study subjects. IMRA trends and graphs real-time laboratory values enabling physicians and medical monitors to respond faster to important safety signals earlier in the development process.

Tom O’Leary, President, ICON Central Laboratories, commented:  “IMRA satisfies an important need in clinical trials by reducing data review times, which in turn, improves the management of study subjects and enables physicians to expedite the medical management of clinically significant findings.”  He continued: “By automating a currently labour intensive process, we can drive down development costs for sponsors while offering 24/7, global access to the latest laboratory data, including detailed analysis of potential trends, signals, alerts and patient-specific data.”

IMRA was developed by ICON physicians specifically for use by fellow physicians, so the application is easy to use and displays data in intuitive ways.  On average, the client data within the application is no more than a few hours old, allowing for real-time evaluation of trends, signals and alerts.  Additional features of the application include up-to-date alert overviews, intuitive data trending, detailed subject profiling and comprehensive data export tools.

About ICON plc:

ICON plc is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. The Company specialises in the strategic development, management and analysis of programs that support clinical development – from compound selection to Phase I-IV clinical studies. ICON currently employs over 7,300 employees, operating from 71 locations in 39 countries.  For further information, please visit www.iconplc.com

About ICON Central Laboratories

ICON Central Laboratories, a division of ICON plc, provides full service, global central laboratory services from  facilities in New York, Dublin and Singapore, and India . An extensive test menu of safety, esoteric and custom-developed assays, including global flow cytometry, is complemented by dedicated, sponsor-specific project teams and a single, comprehensive database for each study as well as a user-friendly, web-based, secure remote data access system. ICON Central Laboratories also offers a unique service to manage and compile laboratory data when a client’s study requires the use of local laboratories.

Latest stories